Results 261 to 270 of about 4,355,944 (375)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
A. Lièvre +12 more
semanticscholar +1 more source
Angubindin‐1 binds angulin‐1/‐3 at tricellular tight junctions, enhancing intestinal macromolecule permeation. Alanine scanning identified six essential residues (L562, L598, E638, V640, Y643, and K644) of angubindin‐1 critical for binding to angulin‐1/‐3 and permeation‐enhancing activity, providing insights for the development of targeted noninvasive ...
Taiki Kuzu +8 more
wiley +1 more source
To be or not to be a protein coding mutation, that's the question! [PDF]
De Groote D +3 more
europepmc +1 more source
The impact of Hnrnpl deficiency on transcriptional patterns of developing muscle cells
We performed nanopore whole‐transcriptome sequencing comparing RNA from Hnrnpl‐knockdown versus control C2C12 myoblasts to investigate the contributions of Hnrnpl to muscle development. Our results indicate that Hnrnpl regulates the expression of genes involved with Notch signaling and skeletal muscle, particularly splicing patterns of specific muscle ...
Hannah R. Littel +8 more
wiley +1 more source
Deep Learning Predicts EGFR Mutation Status from Histology Images in Non-Small Cell Lung Cancer. [PDF]
Park J +21 more
europepmc +1 more source
Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man.
Eric P. Smith +8 more
semanticscholar +1 more source
Rethinking plastic waste: innovations in enzymatic breakdown of oil‐based polyesters and bioplastics
Plastic pollution remains a critical environmental challenge, and current mechanical and chemical recycling methods are insufficient to achieve a fully circular economy. This review highlights recent breakthroughs in the enzymatic depolymerization of both oil‐derived polyesters and bioplastics, including high‐throughput protein engineering, de novo ...
Elena Rosini +2 more
wiley +1 more source
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib. [PDF]
Shi Y +15 more
europepmc +1 more source

